1[1]Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovsecular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction[J]. Circulation, 1997, 95: 2329-2331.
2[2]Hulley S, Grady D, Bush T, et al. Randomized trail of estrogen plus progestin for secondary prevention of coronary heart disssee in postmenopausal women [J]. JAMA, 1998, 280: 605-613.
3[3]PEPI Trail Group. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women : the Postmenopausal Estrogen/Progestin Interventions (PEPI) trail[J]. JAMA, 1995, 273: 199-208.
4[4]Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen/progeatin HRT:effects on serum lipids and lipoproteins[J]. Am J Obstet Gynecol, 1992 , 151: 746-750.
5[5]Holme I. A analysis of randomized trails evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence[ J ]. Circulation,1990, 82: 1916-1924.
6[6]Berg K, Dahlen G, Christophersen B, et al. Lp (a) Lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin. Survival Study[ J]. Clin Genet, 1997, 52: 254-261.
7[7]Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after monopause[J]. JAMA, 2000, 283: 1845-1852.
8[8]Sbarouni E, Kroupis C, Kyriakides ZS, et al. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease [J]. Eur Heart J, 2000 , 21: 975-980.
9[9]Falco C, Tormo G, Estelles A, et al. Fibrinolysis and lipoprotein (a) in women with coronary artery disease, Influence of hormone replacement therapy [J]. Haematologica , 2001, 86: 92-98.
10[10]Grodstoin F, Stampfer MJ, Colditz GA, et al. Postmenopausal Hormone Therapy and Mortality[J]. N Engl J Med, 1997, 336:1769-1775.
